Immunotherapy-induced cholestasis in cancer: insights from the two real-world pharmacovigilance databases of FAERS and vigiBase
{{output}}
Background: The U.S. Food and Drug Administration (FDA) recently issued a safety alert regarding cholestasis as a potential adverse reaction to immune checkpoint inhibitors (ICIs) therapy. However, the underlying mechanisms of IC... ...
